Forest Laboratories, Inc. Announces Positive Phase III Study Results for Nebivolol and Valsartan Combination in Hypertension
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from an 8-week pivotal Phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
Help employers find you! Check out all the jobs and post your resume.
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from an 8-week pivotal Phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
Help employers find you! Check out all the jobs and post your resume.